Download PDF
Hamostaseologie 2009; 29(01): 76-79
DOI: 10.1055/s-0037-1616946
Original article
Schattauer GmbH

Chronic immune thrombocytopenic purpura

New agents
F. Rodeghiero
1   Department of Cell Therapy and Hematology (Director: Francesco Rodeghiero), San Bortolo Hospital, Vicenza, Italy
,
M. Ruggeri
1   Department of Cell Therapy and Hematology (Director: Francesco Rodeghiero), San Bortolo Hospital, Vicenza, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

First generation thrombopoietic growth factors (rhTPO and PEG-rHuMGDF), investigated in the early 2000s, proved effective in increasing platelet count in normal volunteers, in thrombocytopenia due to chemotherapy and also in a few cases of immune thrombocytopenic purpura (ITP). These agents did not complete their clinical development since one of them induced antibodies in the recipients that cross reacted with endogenous thrombopoietin (TPO), thus causing thrombocytopenia. This promoted the ingenious design of a new generation of thrombopoietic growth factors having no sequence homology with natural TPO. The two main agents are romiplostim, a peptibody already approved for clinical use in USA and eltrombopag, a non-peptide, orally active small molecule. In open label and placebo-controlled trials both agents proved to predictably increase platelet count in normal volunteers and in patients with ITP. With appropriate dosages (1–10 µg/kg weekly sub cutaneously for romiplostim; 50–75 mg/die per os for eltrombopag ) a platelet increase becomes significant after 7–10 days and peaks between 10–14 days. By dis -continuing treatment, platelet count returns to baseline level in 10–15 days. The response rate with both agents is above 70–80%, also in patients that had undergone several lines of treatment, or that have failed splenectomy. The response is maintained during the treatment, but is almost invariably lost even after several months of successful administration. Due to the lack of a curative potential and to the incomplete knowledge of long-term side effects, the place of these new drugs in the management of ITP is still unsettled and their use is best restricted to refractory patients or in preparation of splenectomy. It seems however that a new paradigm in the treatment of ITP has been established where the focus is not on reducing platelet consumption but on increasing platelet production.

Keywords

Immune thrombocytopenia - thrombopoietin receptor agonist - therapy
 

  • References

  • 1 Jenkins JM, Williams D, Deng Y. et al. Phase 1 clinical study of eltrombopag, oral, nonpeptide thrombopoietin receptor agonist. Bood 2007; 109: 4739-4741.
    PubMedGoogle Scholar
  • 2 Kumagai Y, Fujita T, Okazi M. et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis – stimulating peptibody in healty Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 2007; 47: 1489-1497.
    CrossrefPubMedGoogle Scholar
  • 3 Bussel JB, Kuter DJ, George JN. et al. AMG 531, a thrombopoiesis – stimulating protein, for chronic ITP. N Engl J Med 2006; 355: 1672-1681.
    CrossrefPubMedGoogle Scholar
  • 4 Newland A, Caulier MT, Kappers-Klunne M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135: 547-553.
    CrossrefPubMedGoogle Scholar
  • 5 Bussel JB, Cheng G, Saleh MN. et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic Purpura. N Engl J Med 2007; 357: 2237-2247.
    CrossrefPubMedGoogle Scholar
  • 6 Kuter DJ, Bussel JB, Lyons RM. et al. Randomized, controlled, 6-month evaluation of AMG531 in patients with chronic immune thrombocytopenic purpura. Lancet 2008; 371: 395-403.
    CrossrefPubMedGoogle Scholar
  • 7 Ballem PA, Segal GM, Stratton JR. et al. Mechanism of thrombocytopenia in chronic autoimmune thrombocytopenic purpura: evidence for both impaired platelet production and incresed platelet clearance. J Clin Invest 1987; 80: 33-40.
    CrossrefPubMedGoogle Scholar
  • 8 Gernsheimer T, Stratton J, Ballem PJ, Slichter SJ. Mechanism of response to treatment in auto-immune thrombocytopenic purpura. N Engl J Med 1989; 320: 974-980.
    CrossrefPubMedGoogle Scholar
  • 9 Hoffman R, Zaknoen S, Yang HH. et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985; 312: 1170-1174.
    CrossrefPubMedGoogle Scholar
  • 10 Chang M, Nakagawa PA, Williams SA. et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-895.
    CrossrefPubMedGoogle Scholar
  • 11 Kosugi S, Kurata Y, Tomiyama Y. et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93: 704-706.
    CrossrefPubMedGoogle Scholar
  • 12 Kelemen E, Cserhati I, Tanos B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol Basel 1958; 20: 350-355.
    CrossrefPubMedGoogle Scholar
  • 13 Vigon I, Mornon JP, Cocaut L. et al. Molecular cloning and characterization of MPL, the human homology of the v-mpl oncogene: identification of a member of the hemopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 1992; 89: 5640-5644.
    CrossrefPubMedGoogle Scholar
  • 14 de Sauvage FJ, Hass PE, Spencer SD. et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand. Nature 1994; 369: 533-538.
    CrossrefPubMedGoogle Scholar
  • 15 Lok S, Kaushansky K, Holly RD. et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994; 369: 565-568.
    CrossrefPubMedGoogle Scholar
  • 16 Wenlding F, Maraskovky E, Debili N. et al. CMPL ligand is a humoral regulator of megakaryocytopoiesis. Nature 1994; 369: 571-574.
    CrossrefPubMedGoogle Scholar
  • 17 Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
    CrossrefPubMedGoogle Scholar
  • 18 Kuter DJ. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Eur J Haematol 2008; 69 Suppl 9-18.
    PubMedGoogle Scholar
  • 19 Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol 2007; 44: S35-S45.
    CrossrefPubMedGoogle Scholar
  • 20 George JN, Terrell DR. Novel thrombopoietic agents: a new era for management of patients with thrombocytopenia. Haematologica 2008; 93: 1445-1449.
    CrossrefPubMedGoogle Scholar
  • 21 Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68: 901-912.
    CrossrefPubMedGoogle Scholar
  • 22 Stasi R, Stipa E, Masi M. et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-442.
    CrossrefPubMedGoogle Scholar
  • 23 George JN, Woolf SH, Raskob GE. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
    PubMedGoogle Scholar
  • 24 British Committee for Standards in Haematology General Haematology Task Force.. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-596.
    CrossrefPubMedGoogle Scholar
  • 25 Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura. Blood 2005; 106: 2244-2251.
    CrossrefPubMedGoogle Scholar
  • 26 Cheng Wong R, Yoo J, Chui C. et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349: 831-836.
    CrossrefPubMedGoogle Scholar
  • 27 Mazzucconi MG, Fazi P, Bernasconi S. et al. Therapy with high-dose dexamethasone in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109: 1401-1407.
    CrossrefPubMedGoogle Scholar
  • 28 Neylon AJ, Saunders PWG, Howard MR. et al. Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122: 966-974.
    CrossrefPubMedGoogle Scholar
  • 29 Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand H. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554.
    CrossrefPubMedGoogle Scholar
  • 30 Cortelazzo S, Finazzi G, Buelli M. et al. High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 1991; 77: 31-33.
    PubMedGoogle Scholar
  • 31 Kojouri K, Vesely SK, Terrel DR. et al. Splen -ectomy for adult patients with idiopathic thrombo cytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634.
    CrossrefPubMedGoogle Scholar
  • 32 Sailer T, Lechner K, Panzer S. et al. The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 2006; 91: 1041-1045.
    PubMedGoogle Scholar
  • 33 McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 2004; 104: 956-960.
    CrossrefPubMedGoogle Scholar
  • 34 Firkin BG, Hunt HA, Jane SM. Management of refractory idiopathic thrombocytopenia. Blood Rev 1988; 2: 149-156.
    CrossrefPubMedGoogle Scholar
  • 35 Berchtold P, McMillan R. Therapy of chronic idiopathic thrombocytopenic purpura in adults. Blood 1989; 74: 2309-2317.
    PubMedGoogle Scholar
  • 36 Manoharan A. Treatment of refractory idiopathic thrombocytopenic purpura in adults. Br J Haematol 1991; 79: 143-147.
    CrossrefPubMedGoogle Scholar
  • 37 Mc Millan R. Therapy for adults with refractory chronic immune thrombocytopenic purpura. Ann Intern Med 1997; 126: 307-314.
    CrossrefPubMedGoogle Scholar
  • 38 Bussel JB. Novel approaches to refractory immune thrombocytopenic purpura. Blood Rev 2002; 16: 31-36.
    CrossrefPubMedGoogle Scholar
  • 39 Provan D. Fifty years of idiopathic thrombocytopenic purpura (ITP): management of refractory ITP in adults. Br J Haematol 2002; 118: 933-944.
    CrossrefPubMedGoogle Scholar
  • 40 Vesely SK, Erdue JJ, Rizvi MA. et al. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy. Ann Int Med 2004; 140: 112-120.
    CrossrefPubMedGoogle Scholar
  • 41 Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current strategies for investigation and management. Br J Haematol 2008; 143: 16-26.
    CrossrefPubMedGoogle Scholar
  • 42 Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000; 12: 1630-1638.
    PubMedGoogle Scholar
  • 43 Cooper N, Woloski BM, Fodero EM. et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. Blood 2002; 15: 1922-1927.
    PubMedGoogle Scholar
  • 44 George JN, Raskob GE, Vesely SK. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol 2003; 74: 161-169.
    CrossrefPubMedGoogle Scholar
  • 45 Arnold D, Dentali F, Crowther MA. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
    CrossrefPubMedGoogle Scholar
  • 46 Godeau B, Porcher R, Fain O. et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008; 112: 999-1004.
    CrossrefPubMedGoogle Scholar
  • 47 Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106: 1532-1537.
    CrossrefPubMedGoogle Scholar